The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or
in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that
express pre-defined Immatics tumor targets.
Biological: IMA101 product
Biological: Recombinant human interleukin-2
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02876510
Ages eligible for Study
18 Years to 65 Years
Genders eligible for Study
Accepts Healthy Volunteers
All locations for NCT02876510
United States (1)
Houston, Texas, United States, 77030
View full eligibility
Tris trial is registered with FDA with number: NCT02876510. The sponsor of the trial is Immatics US, Inc. and it is looking for 38 volunteers for the current phase.
Official trial title: Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.